Research News

Research News | Jul. 17, 2012

Race-Related Preferences In Lupus Treatments

The researchers hoped to learn about possible differences in treatment preferences for lupus among members of different racial/ethnic patient groups, as well as demographic or clinical characteristics associated with such preferences.

Research News | Jun. 21, 2012

New American College of Rheumatology Guidelines for Lupus Nephritis

To update the ACR guidelines for the management of lupus nephritis, a team of lupus experts from around the country collaborated with the ACR. The researchers utilized extensive literature searches and expert opinions to develop the updated guidelines.

Research News | Mar. 22, 2012

Lupus Biomarker Changes Key to Benlysta Therapy

The findings highlight specific kinds of changes in lupus biomarkers that are most associated with effective use of belimumab in the treatment of lupus.

Research News | Feb. 17, 2012

Dynamics of Lupus within First Five Years of Diagnosis

The results of this study reveal differences in autoantibody profiles over time in people with lupus, with important ethnicity-related differences, and their relationship to lupus-mediated organ damage over time.

Research News | Jan. 20, 2012

First Ever Study of Cholesterol-Lowering Drugs in Children With Lupus

The researchers hoped to learn about the safety and efficacy of atorvastatin (Lipitor®) in reducing cholesterol in children with lupus.

Research News | Dec. 02, 2011

Interview-Driven, Patient-Reported Lupus Damage

As people with lupus have become increasingly educated about their disease and involved in their medical care, input from patients about their condition has become increasingly important and useful. Recently, the Lupus Damage Index Questionnaire (LDIQ) was developed for this purpose and captures the spectrum of knowledge acquired from the SDI in a patient-reported questionnaire.

Research News | Sep. 29, 2011

New Experimental Molecule Neutralizes Lupus Autoantibodies

For years, researchers have investigated the possibility of inhibiting the actions of lupus-related autoantibodies to reduce the extent of organ damage. Further research in this area has the potential to facilitate the development of new therapies for people with lupus.

Research News | Apr. 08, 2011

Biomarkers Predict Success of Lupus Nephritis Drug Therapy

Since lupus nephritis can be severe and the therapy can be toxic, it is important to be able to predict which patients would most benefit from long-term treatment.